UroGen Pharma Ltd. Ordinary Shares
URGNUroGen Pharma Ltd. is a biotechnology company focused on developing innovative solutions for urological and uro-oncological conditions. The company's portfolio includes targeted therapies designed to improve treatment outcomes for patients with conditions such as bladder cancer and other genitourinary diseases. UroGen aims to leverage advanced drug delivery technologies to enhance safety and efficacy in urological treatments.
Company News
UroGen Pharma's Chief Medical Officer Mark Schoenberg sold 10,000 shares worth $400,000 on July 9, 2026, under a pre-established Rule 10b5-1 trading plan adopted in August 2025. Despite the sale, Schoenberg retains 119,763 shares valued at $4.82 million. The transaction should not be viewed negatively as it was scheduled long in advance and the C...
UroGen Pharma's Chief Medical Officer Mark Schoenberg sold 5,222 shares for approximately $143,000 on June 8, 2026, reducing his holdings by 3.60%. While his remaining stake of 139,763 shares keeps his interests aligned with investors, the sale follows a pattern of regular dispositions over the past year. The company faces headwinds from an upcom...
A national survey of over 1,100 bladder cancer patients conducted by the Bladder Cancer Advocacy Network (BCAN) reveals that nearly 80% of patients report fear of recurrence, with rates exceeding 90% among those under 50. The report documents significant procedural burden, with many patients undergoing five or more cystoscopies. UroGen Pharma com...
A comprehensive survey of over 1,100 bladder cancer patients reveals significant gaps in care despite advances in treatment. Key findings include diagnostic delays for women (45% initially misdiagnosed with UTIs), inadequate mental health support (41% never offered resources), and financial barriers affecting treatment decisions, particularly for...
Wildcat Capital Management, the family office of late billionaire David Bonderman, completely exited its position in UroGen Pharma by selling 495,606 shares worth $6.79 million in Q3. Despite UroGen's impressive 113% one-year rally, the exit signals disciplined profit-taking rather than loss of confidence, as biotech winners often see valuation r...
